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Oral hairy leukoplakia (HLP) lesions frequently contain defective Epstein-Barr virus (EBV) genomes with
deletions in the EBNA-2 gene that abundantly replicate and persist within the lesion. To characterize these
viral strains and recombinant variants, the EBNA-2 gene in EBV DNA from several different HLP biopsy
specimens was analyzed. Amplification of EBNA-2 coding sequences by PCR demonstrated the presence in
HLP of intact EBNA-2 genes as well as a varnety of internally deleted variants of both EBNA-2A and EBNA-2B.
Some of the deletion variants evolved within the HLP lesion from intact EBNA-2 genes, while other variants
appeared to be transmissible strains that directly infected the lesion. Intrastrain recombination within the
HLP lesion also generated variation within the EBNA-2 polyproline region. Cloning and sequencing of HLP
cDNA demonstrated transcription from the internally deleted EBNA-2 open reading frame, indicating that
these variant genes are expressed in HLP. Comparative analysis of the HLP EBNA-2 sequences confirmed
previous findings of EBV coinfection with multiple types and strains. Sequence variation of these wild-type
genes demonstrated that EBNA-2A sequences distinguish at least two separate strains and a variety of
substrains of EBV type 1. Two of the HLP EBNA-2A sequences contained amino acid changes in a cytotoxic
T-cell epitope within an otherwise highly conserved region of the gene. These data indicate that EBV
coinfection, strain variation, and recombination within the EBNA-2 gene are common features of HLP and
suggest that the expression of internally deleted EBNA-2 variants could contribute to EBV pathogenesis in
permissive infection.
Oral hairy leukoplakia (HLP) is an oral mucosal lesion
characterized by the productive replication of the Epstein-Barr
virus (EBV) within squamous epithelial cells of the lateral
borders of the tongue, occurring most commonly in patients
infected with the human immunodeficiency virus (15). Some
HLP lesions are coinfected with both EBV type 1 (EBV-1) and
EBV-2, on the basis of typing of the Epstein-Barr nuclear
antigen 2 (EBNA-2) gene, and some HLP lesions may be
coinfected with multiple strains of the same EBV type (39). In
HLP, the productively replicating EBV recombines within and
around the EBNA-2 gene, generating a heterogeneous group
of viral variants that may be defective for EBNA-2 function
(39). On the basis of analyses of sequential HLP biopsy
specimens from the same patient, virus variants containing
EBNA-2 gene rearrangements are capable of replicating effi-
ciently and persisting within a lesion (39).
PCR amplification of the EBNA-2 coding sequence from
HLP DNA generated products representing the full-length
sequence, as well as a variety of smaller products suggestive of
internally deleted forms of the gene (39). The heterogeneity of
internally deleted EBNA-2 variants detected for both
EBNA-2A (EBV-1) and EBNA-2B (EBV-2) in different HLP
specimens suggested that they represented EBNA-2 recombi-
nation events within the lesion rather than superinfections with
multiple independent strains. Their presence in a majority of
the HLP specimens examined indicated that these variants
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occur frequently in HLP and may be important in productive
EBV infection (39).
In this study, the EBNA-2 rearrangements were analyzed in
six different HLP biopsy specimens by PCR amplification and
sequencing. Several different patterns of genetic deletion were
detected within both the polyproline and unique sequences of
EBNA-2. Examination of EBNA-2 transcription indicated that
internally deleted EBNA-2 genes are expressed in HLP le-
sions. Some of the variants evolved during viral replication
within the HLP lesions, while others appeared to be indepen-
dent strains. Sequence variation of the EBNA-2 gene defined
at least two different strains of EBV-1 and confirmed that some
HLP lesions are coinfected with multiple types, strains, or
substrains of EBV.
MATERIALS AND METHODS
PCR amplification. HLP biopsy specimens were obtained
from human immunodeficiency virus-seropositive volunteer
patients, and the DNA was extracted as described elsewhere
(12, 28). Single-stranded DNA oligonucleotides synthesized
for use as PCR and sequencing primers are listed in Table 1.
Primer sequences were designed from regions of the EBNA-2
gene common to both EBNA-2A and EBNA-2B and amplified
both types of EBV DNA with equal efficiency. PCR amplifi-
cations of HLP DNA using oligonucleotides 1 and 8, and of
HLP cDNA using oligonucleotides 9 and 8, were performed
with 2 U of Vent DNA polymerase (New England Biolabs,
Beverly, Mass.); a 1:10 dilution of 1OX reaction buffer as
supplied with the Vent polymerase; 200 ,uM (each) dATP,
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TABLE 1. Synthetic oligonucleotides for PCR,
sequencing, and probes














dGTP, dCTP, and dTTP; and a 0.5 pM concentration of each
primer in 50- or 100-jil reaction volumes. In some cases,
7-deaza-dGTP (Boehringer Mannheim, Indianapolis, Ind.)
was substituted for dGTP in a ratio of 3:1 to increase ampli-
fication efficiency. Amplification proceeded for a total of 40
cycles with denaturation at 98°C for 1 min, annealing at 55°C
for 1 min, and extension at 72°C for 1.5 min. PCR amplifica-
tions of HLP cDNA using oligonucleotides 9 and 10 were
performed with 1 U of Taq DNA polymerase (Promega,
Madison, Wis.); a 1:10 dilution of lOX reaction buffer as
supplied with the Taq polymerase; 200 ,uM (each) dATP,
dCTP, and dTTP; 50 j±M dGTP; and 150 ,uM 7-deaza-dGTP
(Boehringer Mannheim) with a 0.5 pM concentration of each
primer in a 20-,ul reaction volume. Amplification proceeded
for a total of 40 cycles with denaturation at 94°C for 1 min,
annealing at 55°C for 1 min, and extension at 72°C for 1 min.
RNA purification and cDNA synthesis. RNA was isolated
from DNA by ultracentrifugation on a 4 M guanidine thiocy-
anate-cesium chloride step gradient as described previously
(12). Residual DNA in the RNA was digested with DNase I
(Boehringer Mannheim). After priming with oligo-dTTP,
cDNA was synthesized from 20 p,g of HLP RNA with Super-
script reverse transcriptase (Gibco BRL, Grand Island, N.Y.)
in the presence of 100 jiWM (each) dATP, dCTP, dGTP, and
dTTP.
Probes and Southern blots. Restriction enzyme-digested
HLP DNA and PCR products were subjected to agarose gel
electrophoresis, transferred to a supported nitrocellulose
membrane (Micron Separations Inc., Westboro, Mass.), and
hybridized by Southern blot. The RNA probes designated
2A-YH and 2B-YH, which have been described elsewhere
(39), were synthesized from cloned EBV DNA fragments using
[a- 2P]UTP (Amersham, Arlington Heights, Ill.) and SP6
RNA polymerase (Promega). These probes identify both the
BamHI Y and H portions of the EBNA-2 gene and also
differentiate between the EBNA-2A and EBNA-2B forms of
the gene. RNA probe 2A-Y contains the EBV sequence from
the HindIll site in BamHI-Y (coordinate 48039) to the
polyproline region of the EBNA-2A gene (coordinate 48737).
RNA probe 2A-dH contains the sequence from the NcoI site in
EBNA-2A (coordinate 49467) to the AhalIl site in U2 (coor-
dinate 50305) of the BamHI H fragment. Probes 2A-Y and
2A-dH hybridize to EBNA-2 and surrounding sequences from
the BamHI Y and H fragments, respectively. These two probes
were synthesized from cloned DNA fragments by using
[a-32P]UTP (Amersham) and T3 or T7 RNA polymerase
(Promega). Single-stranded oligonucleotide 11 (Table 1) was
labeled with [y-32P]ATP (Amersham) and T4 polynucleotide
kinase (New England Biolabs) for use as an oligoprobe.
Cloning ofPCR products. In some cases, the entire contents
of a PCR mixture were cloned, while in other cases, specific
bands were isolated by gel electrophoresis and purified with
the GeneClean Kit (Bio 101, La Jolla, Calif.) before further
amplification and cloning. XbaI and PstI restriction enzyme
sites within PCR primers 1 and 8, respectively, allowed efficient
cloning into plasmid vector pGem3Z (Promega). PCR prod-
ucts generated from primers 9 and 8 were cloned with restric-
tion enzymes SmaI and PstI. Ligated PCR products and
vectors were grown in Escherichia coli DHSaF'IQ, which is a
recA mutant and deficient for in vitro recombination (Gibco
BRL). Bacterial colonies containing the appropriate cloned
PCR products were identified by in situ hybridization with
probe 2A-YH or 2B-YH. Plasmid DNA for sequencing was
extracted from bacterial cell cultures by alkaline lysis and was
purified on Qiagen-tip columns (Qiagen Inc., Chatsworth,
Calif.) or was isolated as described previously (36).
DNA sequencing. The DNA sequence was obtained from
cloned DNA by the dideoxynucleotide chain termination
method with [a- 5S]ATP (Amersham) and Sequenase (version
2.0) enzyme (United States Biochemical, Cleveland, Ohio).
The sequencing reactions were primed with oligonucleotides
matching the SP6 and T7 RNA polymerase promoter primer
sequences within vector pGem3Z (Promega) as well as oligo-
nucleotides 1 to 8 (Table 1). Sequencing reaction products
were run on 8% denaturing polyacrylamide (Long Ranger; AT
Biochem Inc., Malvern, Pa.) gels with 25% formamide.
RESULTS
DNA structure ofEBNA-2 deletions. To determine the DNA
structure of the EBNA-2 deletion variants detected in HLP
(Fig. 1), HLP DNA from six different human immunodefi-
ciency virus-infected patients (LC, PL, VL, WL, LH, and MT)
was analyzed by PCR amplification, cloning, and sequencing of
the EBNA-2 gene. PCR amplification of HLP DNA from
patient LC demonstrated the presence of four different sizes of
the EBNA-2A coding sequence: 1,360, 1,000, 750, and 420 bp
(Fig. 1). EBV-2 represented by EBNA-2B was not detected.
Three of the four products were cloned and sequenced
(LC1360, LC746, and LC422) and demonstrated several dif-
ferent patterns of internal EBNA-2A deletion (Fig. 2A). All
three clones contained internal deletions within the polypro-
line region as compared with the prototype EBNA-2A strain,
B95-8 (2). Two of the clones, LC746 and LC422, each con-
tained unique, larger deletions of EBNA-2 sequence to the
right of the polyproline region.
Amplification of DNA from patient PL yielded product
bands of 850, 510, and 420 bp of EBNA-2A but not of
EBNA-2B (Fig. 1). A band representing the full-length, intact
form of the gene was not detected. Three clones (PL512,
PL503, and PL422) representing the two smaller product
bands were obtained and sequenced (Fig. 2B). Similar to the
LC clones, each PL clone contained a different sequence
within the polyproline region, including both deletions and an
insertion of sequence as compared with the B95-8 strain. Each
of the three PL clones also contained an identical large
deletion from within sequences to the right of the polyproline
region. The structure of this deletion was identical to that of
clone LC422.
Amplification of DNA from patient VL generated
EBNA-2A PCR product bands of 1,450, 950, and 560 bp (Fig.
1). Clones of the 950- and 560-bp products (VL947 and
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FIG. 1. PCR amplification of the EBNA-2 gene from HLP DNA. HLP DNA from six different patients was amplified by PCR using
oligonucleotide primers 1 and 8 and hybridized to the 2A-YH probe (patients LC, PL, VL, WL, LH, and MT [MT lane A]) and the 2B-YH probe
(MT only [lane B]). These probes differentiate EBV-1 from EBV-2 and identify sequences from both BamHI-Y and -H. PCR product sizes are
given in base pairs.
VL560) were obtained and sequenced (Fig. 2C). The two
clones contained large internal EBNA-2A deletions that dif-
fered from each other and from those of LC and PL. In both
VL947 and VL560, the deletions included the polyproline
region and part of the amino-terminal sequence.
DNA from patient WL was amplified and demonstrated a
440-bp EBNA-2A product without evidence of a full-length,
intact form of the gene (Fig. 1). Cloning and sequencing the
PCR product (WL441) demonstrated another unique, large
deletion that included the polyproline sequence (Fig. 2D). The
deletion in this clone began at the same 5' site as in clone
VL560 but ended at a different 3' site.
Amplification of DNA from patient LH produced 1,350-,
760-, and 560-bp EBNA-2A products (Fig. 1), but only the
760-bp band was cloned and sequenced (LH764) (Fig. 2E).
This clone also contained a large deletion that included the
polyproline region. It differed from the deletions described for
the LC, PL, VL, and WL clones.
Amplification of DNA from patient MT yielded PCR prod-
uct bands of 1,460 bp (EBNA-2A), 1,400 bp (EBNA-2B), and
980 bp (EBNA-2B) (Fig. 1). Clones representing the 1,460-
and 980-bp products (MT1444 and MT982) were obtained and
sequenced (Fig. 2F). Clone MT1444 contained full-length,
intact EBNA-2A sequence, differing from B95-8 by both a
deletion and a small insertion of sequence within the polypro-
line region. Clone MT982 was EBV-2 (EBNA-2B), and its
polyproline region was identical to that of the laboratory
Burkitt's lymphoma strain AG876 (9). Unlike the EBNA-2A
clones, MT982 contained a unique, large deletion of sequence
at the carboxy-terminal end of the gene.
These HLP EBNA-2 clones demonstrated a variety of
deletion and insertion sites within the polyproline region
(Table 2). In each clone, the EBNA-2 open reading frame was
preserved by the sequence changes. Identical 5' deletion start
sites were detected in clones LC1360 and LC746 and in clones
LC422, PL512, PL503, PL422, and MT1444. Identical 3'
deletion end sites were detected in clones PL512 and PL503
and in clones LC746, LC422, and PL422. Thus, identical
polyproline deletions were detected in LC422 and PL422 and
in PL512 and PL503. Clone PL512 differed from PL503 by the
addition of one copy of the repeated sequence CCACCACCT
between coordinates 48722 and 48759, while MT1444 also
contained one additional copy of the repeated sequence CCC
CCACCA between coordinates 48710 and 48756.
The HLP EBNA-2 clones also demonstrated a variety of
deletion sites within the unique coding sequences (Table 3).
For each of the EBNA-2A clones, the EBNA-2 open reading
frame was disrupted by the large internal deletion, which
introduced a new stop codon 3' to the deletion. The EBNA-2B
clone, MT982, preserved the EBNA-2 open reading frame
after the deletion but also preserved the original stop codon
immediately 3' to the deletion. Identical large deletions were
detected in clones LC422, PL512, PL503, and PL422. Clones
VL560 and WL441 contained identical 5' deletion start sites
but different 3' end sites. Aside from these identities, there was
no apparent sequence homology between deletion start and
end sites within each clone or among different clones (data not
shown).
To verify that the variation among the HLP EBNA-2 clones
represented the in vivo DNA structure of EBNA-2 rather than
in vitro recombination during the PCR and cloning processes,
EBNA-2A DNA from the B95-8 strain was examined after
PCR amplification and cloning under identical conditions. A
previous clone of B95-8 EBNA-2 that has been maintained in
the laboratory for 10 years with repeated subcloning, transfor-
mation, and purification demonstrated complete sequence
stability over that time (data not shown). DNA from that clone
was amplified and cloned in a manner identical to that used for
the HLP DNA. Eighteen clones were examined and contained
the intact EBNA-2A coding sequence. In 17 of the 18 clones,
there was no change in the sequence of the polyproline region,
while 1 clone demonstrated an in-frame deletion of 90 bp. This
deletion did not match any of the polyproline deletion sites of
the HLP clones or the W91 EBV strain (Table 2) and may have
arisen during the PCR amplification process (18). Given the
low (6%) incidence of artifactual polyproline variation gener-
ated by the specific methods and conditions employed in this
study, the polyproline regions described for the HLP EBNA-2
clones likely represent naturally occurring strain and variant
differences.
To verify the origin of the larger deletions, HLP DNA was
examined to detect and quantify the intact and deleted forms
of the EBNA-2 gene present prior to PCR amplification. In the
HLP clones LC746, VL947, VL560, WL441, and LH764, the
EBNA-2 genes contained deletions that spanned the BamHI
restriction enzyme site between BamHI-Y and -H. Therefore,
two probes (2A-Y and 2A-dH) were designed to detect
EBNA-2 and surrounding sequences from each side of the
BamHI-YH restriction site (Fig. 3). For patients LC, VL, WL,
LH, and MT, HLP DNA was digested with BamHI and
hybridized with probes 2A-Y and 2A-dH (Fig. 3). The 2A-dH
probe identified a typical 6.2-kb BamHI H fragment in HLP
specimens LC, VL, VL + 1 mo., and LH. However, in the
specimens LC, VL, VL + 1 mo., WL, and LH, a 7.2-kb
fragment was identified by both the 2A-Y and 2A-dH probes.
The size and hybridization characteristics of the 7.2-kb frag-
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FIG. 2. Strain sequence and structural analysis of the HLP EBNA-2 PCR clones. Diagrams describe the EBNA-2 type, strain, and substrain
and illustrate the structure of the EBNA-2 internal deletions. The DNA sequence and structure of the HLP clones are compared with those of
the appropriate LCL reference strain, B95-8, W91, or AG876. Short vertical lines represent single-base-pair changes in sequence as compared with
the reference strain above. Numbers in parentheses indicate substrain identity of each clone based on EBNA-2 sequence variation. PRO indicates
the polyproline region of EBNA-2. Deletions are illustrated by thin lines. Insertions are illustrated by small rectangles. A stop sign indicates the
location of the first stop codon after a deletion in the new reading frame.
ment were consistent with a fusion of the BamHI Y (1.8-kb)
and H (6.2-kb) fragments resulting from an approximately 0.5-
to 1-kb deletion of EBNA-2 coding sequence spanning the
BamHI restriction site, as predicted by the HLP EBNA-2
clones.
Additionally, a second fragment larger than 7.2 kb in
specimen WL also hybridized with both the 2A-Y and 2A-dH
probes, suggesting the presence of EBNA-2 internal deletion
as well as additional rearrangements in this fragment. For
specimen LH, the 2A-dH probe identified a 6.2-kb BamHI H
fragment, but a corresponding 1.8-kb BamHI Y fragment was
not detected by the 2A-Y probe. This result suggests that
additional EBNA-2 rearrangements have occurred in this HLP
lesion beyond those represented by the 7.2-kb fragment. For
the two specimens WL and MT + 5 mo., typical 1.8-kb BamHI
Y and 6.2-kb BamHI H fragments were not detected, indicat-
ing that the 7.2-kb EBNA-2 deletion variants were the pre-
dominant forms of EBV replicating in these two HLP lesions.
Remarkably, the 7.2-kb EBNA-2 deletion variant of patient
VL persisted within the lesion over a 1-month period. In all
HLP specimens, the quantity of the 7.2-kb EBNA-2 deletion
variants exceeded 50 copies per cell. Thus, for these HLP
specimens, EBV molecules consistent with both intact and
internally deleted forms of the EBNA-2 gene were detectable
n
VOL. 68, 1994
7922 WALLING ET AL.
TABLE 2. EBNA-2 polyproline deletions









W91 strain 48701 48715
B95-8 PCR control 48722 48802
a Coordinates are given according to the numbering of the genome of the
B95-8 strain (2).
b The clone also contained an insertion of sequence into the EBNA-2
polyproline region (see text).
in abundance in the original HLP DNA before PCR amplifi-
cation. Amplification of HLP DNA generated products that
accurately detected the presence of the different forms of the
EBNA-2 gene within the HLP lesion. Additionally, the size
correlation between the PCR products and the HLP EBNA-2
clones indicated that the unique sequence deletions of these
EBNA-2 genes did not arise during the cloning process.
EBNA-2 sequence variation and strain identification. Al-
though the EBNA-2A gene (EBV-1) is highly conserved, the
laboratory lymphoblastoid cell line (LCL) strain W91 is differ-
entiated from LCL strain B95-8 by 13 nucleotide substitutions
and a codon insertion (Table 4) (2, 7). With a majority of the
changes occurring in the nonessential divergent region and
with largely conserved amino acid sequences, B95-8 and W91
are functionally identical in lymphocyte transforming and
transactivating assays (7). Previously, partially sequenced wild-
type EBNA-2A genes from African and New Guinean isolates
were found to closely resemble the W91 strain (1). In the
present study, a large degree of sequence variation was de-
tected in EBNA-2A genes cloned from HLP specimens; how-
ever, the sequences of most of the clones conformed to the
sequence patterns of either the B95-8 strain or the W91 strain.
In Fig. 2, vertical lines above the horizontal bars represent
the locations of single-base-pair changes in the EBNA-2
sequence relative to the reference strain above. Sequence
variation within the polyproline region has been excluded from
this analysis. All three LC clones contained an EBNA-2
sequence that differed from that of B95-8 by only 2 or 3 bp
(Fig. 2A) but contained none or only one of the W91 signature
TABLE 3. EBNA-2 internal deletions of unique sequences











a Coordinates are given according to the numbering of the genome of the
B95-8 strain (2), except for those of HLP clone MT982, which are given as the
















FIG. 3. EBNA-2 deletion variants in vivo. Eight samples of HLP
DNA from five different patients (LC, VL at two sequential time
points, WL, LH, and MT at three sequential time points) were
digested with BamHI and hybridized in duplicate with probes 2A-Y
and 2A-dH, whose hybridization domains are shown by the hatched
bars above the schematic diagram of the EBNA-2 gene region.
Reconstructions of Raji EBV LCL DNA indicate the EBV genome
copy number per cell. Fragment sizes are indicated in kilobases.
changes. Therefore, the LC clones represented substrains of
the B95-8 strain. Clone LC746 contained a sequence in its
undeleted regions that was identical to that in LC1360, but
both differed from the clone LC422 sequence by 4 bp in the
small amount of undeleted sequence common to all three. The
sequence identity between LC1360 and LC746 indicated sub-
strain identity between these two clones and implied an
evolutionary process within the lesion, generating the large
deletion of LC746 from an intact form of the gene represented
by LC1360. Similarly, the variation between the polyproline
regions of these two clones indicated a second site of intra-
strain viral recombination. The sequence variation of the
LC422 clone identified it as a separate B95-8 substrain, and its
presence in the HLP lesion implied coinfection of the HLP
lesion with two different B95-8 substrains of the same EBV
type, as suggested for HLP by previous studies (39).
All three PL clones contained identical sequences in their
undeleted regions that differed only slightly from that of B95-8
(Fig. 2B), with no W91 signature changes, indicating a B95-8
substrain identity between them. As demonstrated by the LC
clones, intrastrain recombination within the polyproline region
generated these three PL variants. Remarkably, the large
deletion was identical in all three PL clones and was identical
to that of clone LC422, while the EBNA-2 sequence between
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TABLE 4. EBNA-2A strain signatures of W91 and MT1444 compared with those of B95-8
B95-8 EBNA-2 Nucleotide Amino acid Conserved or similar EBNA-2 functional Strain Strain
coordinatea codon change change amino acid domain W91 MT1444
48619 39 A-*C Gln--Pro - Amino terminal -+
48628 42 A-*G Asp--Gly - Amino terminal -+
48629 42 C- A Asp-->Gly - Amino terminal -+
48990 163 A->G Arg--Glu - Divergent + +
48991 163 G->A Arg--Glu - Divergent -+
48991 163 G- T Arg->Val - Divergent +
48998 165 C- A Val--Val + Divergent + +
49057 185 A-+G Gln->Arg - Divergent + -
49091 196 G->T Met->Ile + Divergent + -
49113 204 A-*T Thr--Ser + Divergent + -
49136/49137 211/212 -b--CUC -->Leu - Divergent + -
49170 223 C- T Leu-4Leu + Divergent + -
49211 236 C- T Thr--Thr + Divergent - +
49218 239 C- A Gln--Thr - Divergent - +
49219 239 A--C Gln->Thr - Divergent - +
49444 314 T-*C Leu--Ser - Protein binding - +
49449 316 C->A His-*Asn - Protein binding +
49613 370 T--A Pro--Pro + Nonessential +
49754 417 G-*A Thr--Thr + Nonessential +
49777 425 T--C Ile->Thr - Acidic -+
49793 430 C->T Ser--Ser + Acidic -+
49913 470 A-4T Ser--Ser + Acidic +
49923 474 T-*C Tyr--Asn - Acidic +
49930 476 A-*G Glu-->Gly - Nuclear localization + +
a Coordinates listed in this analysis exclude the EBNA-2 polyproline region and EBNA-2 sequences contained within the oligonucleotide PCR primers 1 and 8.
b_-, none.
among these clones from different patients suggested either
that this specific deletion has evolved independently in two
different HLP lesions or that variant strains or substrains
containing this specific deletion and circulating in the commu-
nity have independently infected these two HLP lesions. The
absence of a full-length form of EBNA-2 by PCR in the PL
HLP lesion could suggest infection by this deletion variant
rather than its evolution within the lesion. Regardless of its
origins, the existence of this specific deletion variant in more
than one HLP suggested that it possesses biological advantages
for permissive EBV infection in HLP.
Both VL947 and VL560 contained identical sequences in the
undeleted regions. VL947 contained the signature W91 codon
insertion, and both clones differed from W91 by only a single
nucleotide change (Fig. 2C), indicating W91 substrain identity
of VL947 and VL560. Similar to LC746, both VL clones were
therefore derived from a full-length, parental form of the
EBNA-2A gene, likely represented by the uncloned 1,450-bp
PCR product.
Clone WL441 contained a large deletion encompassing the
most divergent sequence between W91 and B95-8. The se-
quence of WL441 differed from that of W91 by 4 nucleotides
but differed from that of B95-8 by only 1 nucleotide (Fig. 2D).
Thus, clone WL441 likely represented a B95-8 substrain,
separate from the substrains of the LC and PL clones. Anal-
ogous to the PL HLP lesion, no full-length form of EBNA-2
was detected by PCR in the WL HLP lesion, again suggesting
the possibility of direct infection by this EBNA-2-deleted viral
variant.
Although the region of the W91 signature codon insertion
was deleted in this clone, LH764 contained a sequence in the
undeleted regions that closely matched that of W91 (Fig. 2E)
and that matched identically with the undeleted sequences of
the VL clones. Therefore, VL947, VL560, and LH764 may
represent the same W91 substrain independently infecting the
HLP lesions of two patients. Differences in the deletion sites
among these three clones again indicated that deletion site
variation was not sequence specific.
Clone MT982 contained a sequence in its undeleted region
that was nearly identical to the EBNA-2B sequence of the
laboratory Burkitt's lymphoma strain AG876 (Fig. 2F). The
concurrent presence of the EBNA-2A gene within this HLP
lesion, MT1444, confirmed at the sequence level that some
HLP lesions are coinfected with both EBV-1 and EBV-2 (39).
The sequence of MT1444 differed from that of B95-8 by 13
nucleotide substitutions (Fig. 2F). Although three of those
changes matched W91 sequence changes, MT1444 lacked the
signature codon insertion and differed from W91 by 20 nucle-
otide substitutions. The nucleotide and amino acid substitu-
tions of MT1444 are compared with the sequences of both
B95-8 and W91 in Table 4. With significant sequence diver-
gence from both B95-8 and W91, the EBNA-2A sequence of
MT1444 likely represents a new, third strain of EBV-1. On the
basis of the known functional domains of the EBNA-2A
protein (6, 7, 23, 24), the changes in MT1444 would likely not
alter transformation and transactivation functions of this gene
in B lymphocytes.
EBNA-2 transcription in HLP. For each of the Epstein-Barr
nuclear antigens 1 to 6, expression requires unique differential
splicing of a single mRNA transcript before translation (31).
The RNAs of 10 different HLP biopsy specimens from six
different human immunodeficiency virus-infected patients
were reverse transcribed into cDNA and analyzed by PCR
amplification for EBNA-2 specific posttranscriptional process-
ing. In this assay, PCR primers 9 and 10 flanked the intron
between the Y2 and the YH exons (Fig. 4) (31) such that
amplification of the correctly processed EBNA-2 message
generated a 209-bp product. Unspliced mRNA or contaminat-
ing DNA was detected by a 595-bp PCR product. The 209-bp
PCR product was detected in 6 of 10 HLP specimens from four
of the six patients, including patients VL and WL (Fig. 4).
These results indicated that the appropriate transcriptional
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FIG. 4. Expression of the EBNA-2 open reading frame in HLP. Ten samples of HLP cDNA from six different patients (VL, WL at two
sequential time points, PL, NL, CG, and RF at four sequential time points) were amplified by PCR using oligonucleotide primers 9 and 10. These
primers amplify across the intron between the Y2 and the YH exons upstream of the EBNA-2 coding sequence. The PCR products were identified
by hybridization to oligonucleotide probe 11. The 209-bp products represent the correct mRNA splice for EBNA-2 expression, while the 595-bp
products represent unspliced mRNA or contaminating DNA. RT, reverse transcriptase.
processing for the expression of the EBNA-2 open reading
frame occurs and persists in some HLP lesions.
To confirm the presence of the Y2-to-YH splice and deter-
mine if the internally deleted forms of EBNA-2 may be
expressed in HLP, cDNA from patient WL was PCR amplified
with primers 9 and 8, which span both the Y2-to-YH splice site
and the EBNA-2 open reading frame (Fig. 4). Cloning and
sequencing this PCR product from WL cDNA demonstrated
the presence of the Y2-to-YH splice in conjunction with the
internal deletion of the EBNA-2 coding sequence (Fig. 5). The
internal EBNA-2 deletion and the undeleted EBNA-2 se-
quences of the WL cDNA clone matched identically with those
of the WL DNA clone WL441, indicating that the internally
deleted EBNA-2 genes of HLP lesions are transcribed and
appropriately processed to be translated into protein within an
HLP lesion.
DISCUSSION
Previous studies have demonstrated that EBV exists in HLP
as a continuously evolving, heterogeneous population of viral
types, strains, and recombinant variants (39). EBV-1 and
EBV-2 are distinguished by nearly 40% sequence divergence
of the EBNA-2 gene (9) and up to 20% divergence in the
EBNA-3, EBNA-4, and EBNA-6 genes (32). In the laboratory,
EBV strains have been defined by restriction fragment length
polymorphisms arising from sequence variation at restriction
ATG TAA
8-
FIG. 5. Sequence and structural analysis of an HLP cDNA. The
PCR amplification product of oligonucleotide primers 9 and 8 from
patient WL HLP cDNA was cloned and sequenced. It contained the
mRNA splice from exon Y2 to exon YH continuously joined to
EBNA-2 coding sequence that identically matched the sequence and
structure of the HLP DNA clone WL441.
sites and/or variation of repetitive sequences within the frag-
ment (3, 8, 16). Previous and present data demonstrate that
EBV intrastrain recombination within both repetitive and
unique sequences of the EBNA-2 and latent membrane pro-
tein 1 genes generates variants during productive replication in
HLP (27, 39). Thus, in the study of permissive EBV infections,
EBV strains could be more accurately distinguished by se-
quence identity or divergence within genes that are known to
differ between isolates (7, 27).
The present study validates and extends this definition of an
EBV strain by demonstrating that most wild-type EBNA-2A
nucleotide sequences assort with known strain variation from
laboratory LCLs. The one HLP EBNA-2 clone not resembling
either B95-8 or W91 likely represents a third wild-type strain,
although confirmation will require examination of more EBV
isolates. EBV strains may be further divided into substrains on
the basis of additional nucleotide substitutions within a given
EBNA-2A strain sequence. In the HLP of patients LC, PL, and
VL, this definition of EBNA-2A substrain enabled the differ-
entiation between EBV coinfection and the generation of
deletion variants through recombination. The distinction be-
tween EBNA-2A strain and substrain is clearly one of degree
and dependent on the rate of evolutionary changes in vivo
(EBV polymerase errors), the rate of mutation in vitro (E. coli
polymerase errors), and the fidelity of the thermostabile DNA
polymerase used for PCR amplification. On the basis of the
sequence stability of the EBNA-2 clone of B95-8, the contri-
bution of E. coli polymerase to variation appears negligible.
The Vent DNA polymerase used in this study contains a
3'-to-5' proofreading exonuclease activity which results in very
high-fidelity nucleotide incorporation. Therefore, PCR ampli-
fication is also unlikely to be the source of sequence variation.
The biological implications of strain and substrain sequence
variation are unclear, but some amino acid substitutions may
play a role in antigenic variation of a critical viral protein,
resulting in evasion of host immune recognition. In persons
expressing HLA-A11 major histocompatibility complex class I
molecules, the HLA-A11 restricted cytotoxic T-lymphocyte
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human populations with a high prevalence of HLA-A11, the
predominant EBV-1 strain has mutated a single amino acid
residue within that epitope, abrogating the host cytotoxic
T-lymphocyte recognition of that protein (10). For EBNA-2A,
two cytotoxic T-lymphocyte epitopes have been defined: amino
acids 42 to 51, associated with HLA-A2, and amino acids 276
to 291, associated with HLA-B18 (21). The EBNA-2A sub-
strain represented by clones LC1360 and LC746 has mutated
amino acid 42 (Asp-*Asn) within the first epitope. Similarly,
the EBNA-2A strain represented by clone MT1444 has mu-
tated the same amino acid (Asp-*Gly) within the first epitope.
Both of these amino acid changes result in significant side
chain substitutions that may alter the immune processing and
recognition of that epitope in persons expressing HLA-A2 and
possibly other HLA types.
The G+C-rich, repetitive EBNA-2 polyproline region is
dispensable for transactivation and transformation function in
B lymphocytes (7) and varies in length among strains, espe-
cially between EBV-1 and EBV-2 (7, 9). Even two clones of the
same LCL strain (B95-8) from two different laboratories have
evolved a 9-nucleotide difference in polyproline length (2, 9).
Analogous to the variable Gly-Ala amino acid repeats of the
EBNA-1 gene (17), polyproline variation could account for
some of the variation in EBNA-2 protein size detected among
wild-type EBV isolates (13, 14, 34). While homologous recom-
bination is a consistent feature of productive EBV replication
both in vitro and in vivo (27, 38, 39), examples from herpes
simplex virus type 1 suggest that recombination also occurs at
specific G+C-rich recognition sites denoted by specific DNA
conformations (19, 40). Thus, viral recombination within the
EBNA-2 polyproline region could account for the polyproline
variations detected in the same-strain EBNA-2 genes from a
single HLP specimen.
During productive replication both in vitro and in vivo, EBV
recombination within nonrepetitive genome regions generates
viral variants through the deletion, insertion, or juxtaposition
of sequences (4, 20, 28, 29, 35). The heterogeneous DNA of
the P3HR-1 LCL replicates independently and is transmissible
in culture (25), while EBNA-2-deleted variants similar to
P3HR-1 are detectable in oropharyngeal secretions from 15%
of healthy adults and in over 90% of HLP specimens (35, 39).
Present data from HLP indicate that EBNA-2 internal deletion
variants not only arise through recombination within the HLP
lesion but may exist as independent strains as well. Given the
abundance and variety of deletions detected, EBNA-2 appears
to be an exceptionally active region for viral recombination
during productive replication. However, the diversity of sites
utilized in EBNA-2 recombination reveals neither homology
nor sequence specificity nor consistently high G+C content to
suggest a single mechanism of recombination.
Previous studies have not convincingly demonstrated the
expression of the EBNA-2 gene in HLP. EBNA-2 transcripts
were not detected by Northern blotting ofHLP RNA, nor were
they detected in two cDNA libraries of HLP biopsy specimens
(22). The presence of EBNA-2 protein in HLP histologic tissue
sections was reportedly detected in approximately 50% of
specimens by using monoclonal antibody PE2 (33, 37). In the
present study, PCR analysis of HLP cDNA detected EBNA-2
transcripts in approximately two-thirds of the HLP specimens,
including transcription of internally deleted EBNA-2 genes.
Translation of deleted EBNA-2 gene transcripts would pro-
duce proteins lacking the PE2 epitope (7) and probably lacking
many human antibody epitopes, making the putative variant
proteins difficult to detect by immunologic techniques.
The EBNA-2 gene product is required for EBV transforma-
tion of B lymphocytes, differing in its transformation efficiency
between EBNA-2A and EBNA-2B (5). An important regula-
tory gene in B-lymphocyte infection, EBNA-2 transactivates a
number of cellular and viral genes and coordinates the expres-
sion of other EBNA genes (7, 30). Like P3HR-1, EBV strains
deleted for the EBNA-2 gene are transformation incompetent
but can superinfect latent LCLs and replicate efficiently (26,
29, 35). However, the role for EBNA-2 in epithelial infection is
uncertain. Latently infected epithelial cells of nasopharyngeal
carcinoma do not express the EBNA-2 gene (41), and EBNA-2
is not required for productive replication in mucosal epithelial
infections (35).
The abundance and frequency with which EBNA-2-defec-
tive variants occur and persist in HLP suggest positive selection
for the biological properties of these variants (35, 39). The
domains for nuclear localization, protein-protein interactions,
and DNA transcriptional transactivation within the carboxy
terminus of the protein have been deleted from all of the
EBNA-2 variants detected in these HLP lesions (6, 7, 23, 24).
This loss of EBNA-2 function could facilitate the initiation of
viral replication by failing to stimulate latency-associated gene
expression, an advantageous attribute in a permissive environ-
ment. The diversity of internally deleted EBNA-2 genes may
simply reflect positive selection for a variety of random viral
variants that are incapable of expressing a functional EBNA-2
protein.
Alternatively, the expression of the internally deleted
EBNA-2 gene could play an as yet undefined role in permissive
epithelial infection. These genes have preserved some or all of
the amino-terminal domain which is 98% conserved at the
nucleotide level among the HLP EBNA-2A strains and 80%
conserved at the amino acid level between EBNA-2A and
EBNA-2B (9). The maintenance and expression of the
EBNA-2 amino-terminal domain in HLP may indicate viral
conservation of a functionally important domain for permissive
infection of mucosal epithelium. The prevalence and persis-
tence in HLP of the internally deleted EBNA-2 variants
suggest that the role of EBNA-2 recombination in permissive
EBV infection warrants further study.
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